Pharmacologic considerations for therapeutic success with antiretroviral agents

Annals of Pharmacotherapy

Volumn 33, Issue 9, 1999, Pages 989-995

  Fletcher, Courtney V ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antiretrovirals; Human immunodeficiency virus

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV; HIV INFECTIONS; HUMANS; RNA, VIRAL;

EID: 0032845172     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19075     Document Type: Article

References (35)

1. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337: 725-33.
3. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection, implications for clinical management. JAMA 1998;279:1984-91.
4. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998, updates recommendations of the International AIDS Society-USA Panel. JAMA 1998;280:78-86.
5. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992;51:465-73.
6. Fletcher CV, Balfour HH Jr. Variability in the zidovudine serum concentrations. Pharmacotherapy 1996;16:1154-8.
7. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
8. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochrome P450. J Pharmacokinet Biopharm 1996;24:451-73.
9. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413-580.
10. Robbins BL, Rodman J, McDonald C, Srinivas RV, Flynn P, Fridland A. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994;38: 115-21.
11. Gao WY, Agbaria R, Driscoll RJS, Mitsuya H. Divergent antiviral activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994;269:12633-8.
12. Ho HY, Hitchcock MJM. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother 1989;33:844-9.
13. Fletcher CV, Acosta EP, Henry K, Page LM, Gross CR, Kawle SP, et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 1998;64:331-8.
14. Sommadossi JP, Valantin MA, Zhou X-J, Xie M-Y, Moore J, Calvez V, et al. Intracellular phosphorylation of stavudine (d4T) and 3TC correlates with their antiviral activity in naive and zidovudine (ZDV) experienced HIV-infected patients (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1, 1998.
15. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981;6:429-53.
16. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996;2:760-6.
17. Mentre F, Escolano S, Diquet B, Golmard J-L, Mallet A. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationships to long term efficacy and toxicity. Eur J Clin Pharmacol 1993; 45:397-407.
18. Butler KM, Husson RN, Balis FM, Brouwers, P, Eddy J, El-Amin D, et al. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991;324:137-44.
19. Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, et al. Clinical pharmacology of 2′-3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992;165:99-104.
20. Havlir D, Cheesman SH, McLaughlin MM, Murphy R, Erice A, Spector SA, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45.
21. Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996;174: 713-21.
22. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
23. Hoetelmans RMW, Heeswijk RPG, Meenhorst VPL, Mulder JW, Scheele WA, Beijnen FH. Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
24. Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann OT, Overbeck J, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir and saquinavir. AIDS 1997;11:F95-9.
25. Harris M, Durakovic C, Rae S, Raboud J, Fransen S, Shillington A, et al. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J Infect Dis 1998;177:1514-20.
26. Burger DM, Hoetelmans RMW, Hugen PWH, Mulder JW, Meenhorst PL, Koopmans PP, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Therapy 1998;3:215-20.
27. Pithavala Y, Zhang M, Knowles M, Daniels R, Anderson R, Kerr B. Virologic response-plasma concentration relationship in Phase III study of nelfinavir mesylate (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
28. Hoetelmans RMW, Reijer MHE, Weverling GJ, ten Kate RW, Wit FWNM, Mulder JW, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998;12: F111-5.
29. Yarchoan R, Broder S. Strategies for the pharmacological intervention against HTLV-III/LAV. In: Broder S, ed. AIDS, modern concepts and therapeutic challenges. New York: Marcel Dekker, 1987.
30. "Dear Doctor" letter, Merck Research Laboratories, West Point, PA, September 25, 1988.
31. Hsu A, Granneman GR, Cao G, Carothers L, El-Shourbagy T, Baroldi P, et al. Pharmacokinetic interactions between two immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63:453-64.
32. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1998;13:213-24.
33. Hsu A, Granneman GR, Cao G, Carothers L, Japour AJ, El-Shourbagy T, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998;42:2784-91.
34. Spector R, Park GD, Johnson GF, Vesell ES. Therapeutic drug monitoring. Clin Pharmacol Ther 1988;43:345-53.
35. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505.